Prevention programmes of progressive renal disease in developing nations (Review Article)

SUMMARY:  Development of strategies for the early detection and prevention of non‐communicable diseases, including kidney disease, is the only realistic strategy to avert an imminent global health and economic crisis and enhance equity in health care worldwide. In this article, we briefly examine the burden of non‐communicable diseases, including diabetes, hypertension, cardiovascular disease and how chronic kidney disease (CKD) represents a key integrated element in the setting, even in developing countries. A possible explanation of the increasing number of people who have or are at risk to develop CKD in poor countries is also given. A survey of major screening and intervention programmes performed or ongoing globally is then presented, highlighting differences and hurdles of projects planned in developed or developing nations as well as in unprivileged communities in developed countries. Finally, some recommendations on future steps to implement prevention programmes in emerging worlds are provided.

[1]  Miguel Almaguer-López,et al.  Strategies for national health care systems and centers in the emerging world: Central America and the Caribbean--the case of Cuba. , 2005, Kidney international. Supplement.

[2]  R. Dyck Tracking ancient pathways to a modern epidemic: diabetic end-stage renal disease in Saskatchewan aboriginal people. , 2005, Kidney international. Supplement.

[3]  L. Reyes,et al.  Long-term consequences of low birth weight. , 2005, Kidney international. Supplement.

[4]  J. Maccluer,et al.  Kidney disease among the Zuni Indians: the Zuni Kidney Project. , 2005, Kidney international. Supplement.

[5]  B. Caballero A nutrition paradox--underweight and obesity in developing countries. , 2005, The New England journal of medicine.

[6]  M. Mani Experience with a program for prevention of chronic renal failure in India. , 2005, Kidney international. Supplement.

[7]  T. Nagasawa,et al.  Erythropoietin‐resistant anaemia in a predialysis patient with Klinefelter syndrome , 2005, Nephrology.

[8]  Z. Morad,et al.  Prevention of renal failure: The Malaysian experience , 2005, Kidney International.

[9]  G. Remuzzi,et al.  Albuminuria as early test for vascular disease , 2005, The Lancet.

[10]  Hans L. Hillege,et al.  Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria , 2004, Circulation.

[11]  R. Rodby,et al.  An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting , 2004, Journal of Human Hypertension.

[12]  P. Lapuerta,et al.  Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and re , 2004, Diabetes care.

[13]  N. Powe,et al.  Screening for proteinuria in US adults: a cost-effectiveness analysis. , 2003, JAMA.

[14]  Giuseppe Remuzzi,et al.  The future of renoprotection: Frustration and promises , 2003 .

[15]  A. Collins,et al.  Chronic kidney disease and cardiovascular disease in the Medicare population. , 2003, Kidney international. Supplement.

[16]  G. Maguire,et al.  Renal function and cardiovascular risk markers in a remote Australian Aboriginal community. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  R. Nelson,et al.  Testing for microalbuminuria in 2002: barriers to implementing current guidelines. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  David W Dunstan,et al.  Prevalence of kidney damage in Australian adults: The AusDiab kidney study. , 2003, Journal of the American Society of Nephrology : JASN.

[19]  Neil R. Powe,et al.  Lifestyle Factors, Obesity and the Risk of Chronic Kidney Disease , 2003, Epidemiology.

[20]  K. Iseki The okinawa screening program. , 2003, Journal of the American Society of Nephrology : JASN.

[21]  B. Brenner,et al.  Dialysis delayed is death prevented: a clinical perspective on the RENAAL study. , 2003, Kidney international.

[22]  W. McClellan,et al.  Taking a public health approach to the prevention of end-stage renal disease: the NKF Singapore Program. , 2003, Kidney international. Supplement.

[23]  S. Naicker,et al.  End-stage renal disease in sub-Saharan and South Africa. , 2003, Kidney international. Supplement.

[24]  M. Mani Prevention of chronic renal failure at the community level. , 2003, Kidney international. Supplement.

[25]  R. Zatz,et al.  Nephrology in Latin America, with special emphasis on Brazil. , 2003, Kidney international. Supplement.

[26]  Joel Lexchin,et al.  The pharmaceutical industry as a medicines provider , 2002, The Lancet.

[27]  Hans L Hillege,et al.  Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population , 2002, Circulation.

[28]  R. Barsoum Overview: end-stage renal disease in the developing world. , 2002, Artificial organs.

[29]  R. Barsoum End-stage renal disease in the developing world. , 2002, Artificial organs.

[30]  V. Kher End-stage renal disease in developing countries. , 2002, Kidney international.

[31]  M. Dichgans CADASIL: A Monogenic Condition Causing Stroke and Subcortical Vascular Dementia , 2002, Cerebrovascular Diseases.

[32]  B. Dimitrov,et al.  Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial , 2002, The Lancet.

[33]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[34]  T. Usami,et al.  Regional variations in the incidence of end-stage renal failure in Japan. , 2000, JAMA.

[35]  R. Mañalich,et al.  Relationship between weight at birth and the number and size of renal glomeruli in humans: a histomorphometric study. , 2000, Kidney international.

[36]  J. Birkmeyer,et al.  The Cost-Effectiveness of Treating All Patients with Type 2 Diabetes with Angiotensin-Converting Enzyme Inhibitors , 1999, Annals of Internal Medicine.

[37]  J. Mathews,et al.  A new dimension to the Barker hypothesis: low birthweight and susceptibility to renal disease. , 1999, Kidney international.

[38]  S. Yusuf,et al.  Emerging epidemic of cardiovascular disease in developing countries. , 1999, Circulation.

[39]  G. Remuzzi,et al.  The first clinical and epidemiological programme on renal disease in Bolivia: a model for prevention and early diagnosis of renal diseases in the developing countries. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[40]  A. Disney Some trends in chronic renal replacement therapy in Australia and New Zealand, 1997. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  B. Rutkowski,et al.  Treatment of end-stage renal disease in central and eastern Europe: overview of current status and future needs. , 1998, Artificial organs.

[42]  J. Barendregt,et al.  Global burden of disease , 1997, The Lancet.

[43]  B. Kiberd,et al.  Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation , 1995, BMJ.

[44]  C. V. Howard,et al.  The effect of intrauterine growth retardation on the development of renal nephrons , 1992, British journal of obstetrics and gynaecology.

[45]  D. Silverberg,et al.  Routine urinalysis (dipstick) findings in mass screening of healthy adults. , 1987, Clinical chemistry.

[46]  G Rose,et al.  Sick individuals and sick populations. , 1985, International journal of epidemiology.

[47]  G. Eknoyan,et al.  Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[48]  Michael J Lysaght,et al.  Maintenance dialysis population dynamics: current trends and long-term implications. , 2002, Journal of the American Society of Nephrology : JASN.

[49]  G. Remuzzi,et al.  Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. , 2001, Kidney international.

[50]  T A Louis,et al.  Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. , 2001, Journal of the American Society of Nephrology : JASN.

[51]  A. Palmer,et al.  The cost-effectiveness of different management strategies for Type I diabetes: a Swiss perspective , 2000, Diabetologia.

[52]  R Doll,et al.  Mortality from smoking worldwide. , 1996, British medical bulletin.

[53]  Lei‐shi Li,et al.  End-stage renal disease in China. , 1996, Kidney international.